Drug Trial Radar · NCT06948019
Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47)
Last checked: Nov 19, 2026Latest source record: Apr 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
5
Planned (sponsor's estimate)
Start
Aug 2025
Primary completion
Aug 2030
Study completion Aug 2032
Sponsor
- Lead sponsor
- BlackfinBio LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Boston Children's Hospital
- First posted
- Apr 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 months, up to 60 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Safety and Efficacy of AAV9/AP4B1 For Patients with AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47): A Phase 1/2 Single-Center, Open-Label Study of Stereotactic Intra-cisterna Magna Administration. The goal of this clinical trial is to evaluate whether a gene therapy can safely treat children with SPG47, a rare genetic condition that causes progressive spasticity and developmental delays. The main questions it aims to answer are: * Is the gene therapy safe and well tolerated? * Does the gene therapy improve motor function and developmental outcomes? Participants will: * Undergo screening assessments to confirm eligibility * Receive a single dose of the gene therapy vector * Attend follow-up visits for safety monitoring and developmental assessments over the course of five years
Conditions
- HSP
- Hereditary Spastic Paraplegia
- Hereditary Spastic Paraparesis
- Hereditary Spastic Paraplegia Type 50
- Hereditary Spastic Paraplegia Type 47
- Hereditary Spastic Paraplegia Type 51
- Hereditary Spastic Paraplegia Type 52
- SPG47
- AP4B1
- Neurogenetic Disorders
- Neurodevelopmental Conditions
- Movement Disorders
- Gene Therapy
Interventions
BFB-101 (AAV9-CBh-AP4B1)Biological
The AAV9-CBh-AP4B1 biological drug product is an aqueous suspension of a gene transfer vector intended for CSF injection. It consists of replication deficient adeno-associated virus (AAV) vector with the AAV serotype 9 capsid enclosing a single stranded DNA with an expression cassette of AP4B1 driven by CBh promoter.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of unanticipated treatment-related toxicities, Grade 3 or higher in participants with SPG47Time frame: 60 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Boston Children's Hospital
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.